H1N1 New Caledonia

H1N1 Influenza-A Virus New Caledonia/20/99 IVR 116
Cat. No.
BT25560
Source
Synonyms
Appearance
Sterile Filtered colorless solution.
Purity
Greater than 90.0% as determined by ELISA analysis.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza A virus, strain A/ New Caledonia/20/99 IVR 116. The Influenza Virus was purified by Ultracentrifugation with 10-40 % sucrose gradient.

Product Specs

Introduction
Influenza A virus subtype H1N1 has undergone mutations resulting in various strains. These include the Spanish Flu strain, mild human flu strains, endemic pig strains, and strains found in birds. Structurally, the Influenza A virus is a roughly 100nm globular particle encased in a lipid bilayer originating from the host's plasma membrane. This bilayer is embedded with approximately 500 molecules of hemagglutinin ("H") and 100 molecules of neuraminidase ("N"), both integral membrane proteins. Internally, the virus contains 3000 molecules of matrix protein, 8 RNA segments, and numerous nucleoproteins associated with each RNA molecule. Additionally, there are multiple copies of the three subunits of RNA polymerase and some "non-structural" proteins whose functions are not yet fully understood.
Description
This product contains allantoic fluid from 10-day-old embryonated eggs. The eggs were inoculated with the A/New Caledonia/20/99 IVR 116 strain of influenza A virus. The virus underwent purification through ultracentrifugation using a 10-40% sucrose gradient.
Inactivation
This product has been treated with thimerosal and beta-propiolactone for inactivation. While these methods are consistent with inactivation procedures, standard laboratory practices for safe handling of microbiological and viral agents are still required during use.
Physical Appearance
This product appears as a clear, sterile-filtered solution.
Formulation
The H1N1 A/New Caledonia/20/99 IVR solution is formulated with STE, 0.09% sodium azide (NaN₃), and 0.005% thimerosal.
Stability
While A/New Caledonia/20/99 IVR remains stable at 4°C for up to 4 weeks, storage below -18°C is recommended. Repeated freeze-thaw cycles should be avoided.
Purity
ELISA analysis confirms a purity exceeding 90.0% for this product.
Immunological Activity
Tested with anti-influenza A monoclonal antibodies in ELISA.Serological studies of influenza A virus, immunogen for antibody production.

Product Science Overview

Introduction

The H1N1 Influenza-A Virus New Caledonia/20/99 IVR 116 is a strain of the influenza virus that has been extensively studied and utilized in various research and vaccine development efforts. This article delves into the background, genetic characteristics, and significance of this particular strain.

Origin and Classification

The H1N1 Influenza-A Virus New Caledonia/20/99 (IVR-116) was first isolated in New Caledonia in 1999. It belongs to the Orthomyxoviridae family, which includes influenza viruses that infect both humans and animals . The H1N1 subtype is known for its ability to cause seasonal flu outbreaks and has been a subject of significant scientific interest due to its pandemic potential.

Genetic and Antigenic Characteristics

The genetic makeup of the New Caledonia/20/99 strain is closely related to other H1N1 viruses but has unique antigenic properties that distinguish it from other strains. This strain has been used as a reference strain in the development of influenza vaccines due to its stability and representativeness of circulating H1N1 viruses .

Use in Research and Vaccine Development

The New Caledonia/20/99 (IVR-116) strain has been utilized in various research studies to understand the behavior and characteristics of H1N1 viruses. It has also been used in the production of influenza vaccines. The strain is inactivated and partially purified before being used as an antigen reagent in vaccine formulations .

Safety and Handling

The antigen reagent prepared from the New Caledonia/20/99 (IVR-116) strain is considered potentially hazardous and should be handled with care in laboratory settings. It is not intended for administration to humans or animals in the food chain . Proper safety procedures, including the use of protective gloves and avoiding aerosol generation, are recommended when handling this material .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

Influenza-A H1N1 Antibody
Influenza-A Hemagglutinin H1N1, Mouse Antibody
Cat. No.
BT8195
Source
Anhui H7N9
Hemagglutinin-Influenza A Virus H7N9 Anhui 2013 Recombinant
Cat. No.
BT25184
Source
<p><span lang="EN-US">Sf9, Baculovirus cells.</span></p>
H1N1 Beijing
H1N1 Influenza-A Virus Beijing/262/95
Cat. No.
BT25259
Source
H1N1 Taiwan
H1N1 Influenza-A Virus Taiwan/1/86
Cat. No.
BT25849
Source
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.